How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen's (AMGN) Risk-Reward Profile [Yahoo! Finance]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Yahoo! Finance
Zai Lab separately announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer. These developments highlight the dual reality for Amgen of expanding its oncology footprint through external partnerships even as fresh safety concerns emerge around an existing therapy. We'll now examine how the FDA's Tavneos liver injury warning could reshape Amgen's risk profile and overall investment narrative. Uncover the next big thing with 31 elite penny stocks that balance risk and reward. Amgen Investment Narrative Recap To stay in Amgen, you generally have to believe its diversified portfolio and late stage pipeline can offset pricing pressure, biosimilar competition, and rising R&D spend. The Tavneos liver injury warning adds a fresh safety and regulatory overhang, while oncology partnerships like the Zai Lab tie up support the idea that oncology remains a key near term growth catalyst. At the same tim
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative [Seeking Alpha]Seeking Alpha
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy [Yahoo! Finance]Yahoo! Finance
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager TherapyBusiness Wire
- Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.MarketBeat
- Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
ZLAB
Earnings
- 2/26/26 - Miss
ZLAB
Sec Filings
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- ZLAB's page on the SEC website